Login
Companies $QTTB
$8.29 +$0.00 (0.0%) After hours
Q32 Bio Inc. logo

Q32 Bio Inc.

q32bio.com

What Do They Do?

Develops antibody medicines for people with alopecia areata and other autoimmune and inflammatory diseases.

How Do They Make Money?

FY2025 revenue

Do Revenues Turn Into Profits?

Yes. It kept 55 cents of every revenue dollar as net income in FY2025, but spent more cash than it brought in: free cash flow was −$33.5M.

Operating income, FY2025
31% of revenue
▲ Turned profitable vs FY2024 (−$66.1M)
Net income, FY2025
55% of revenue
▲ Turned profitable vs FY2024 (−$47.7M)
Free cash flow, FY2025
−62% of revenue
▲ +51% (Loss) vs FY2024 (−$67.8M)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −21% (Loss)
vs −$7.4M in Q3 FY2025
  • Jul 13, 2026 Reported positive trial results for bempikibart in alopecia areata The company plans to advance bempikibart into a registration-directed program.

Growing. Revenue grew 58% in 4 years, from $34M in FY2021 to $53.7M in FY2025, about 12% a year.

A shift to immune-disease biologics The older report described genetic medicines for rare genetic diseases, including gene editing, gene therapy and antibody-producing gene therapy. The latest report focuses on antibody medicines for autoimmune and inflammatory diseases, led by bempikibart for alopecia areata.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support